臨床検査64巻7号

2020年07月発行

今月の特集1 骨髄不全症の病態と検査

骨髄異形成症候群（MDS）の診断基準を満たさないMDS類似病態

著者： 松田晃¹

所属機関： ¹埼玉医科大学国際医療センター造血器腫瘍科

ページ範囲：P.766 - P.770

Point

●ICUSは1系統以上に原因が特定できない血球減少があり，異形成は存在したとしても軽微である（各系統で10％未満）．

●ICUS患者で1つ以上の骨髄異形成症候群（MDS）に関連する体細胞変異が検出される場合は，CCUSになる．

●CHIPは，1つ以上のMDSに関連する体細胞変異があるが，血球減少はない．

●IDUSは好中球系，赤芽球系，および/または巨核球系の10％以上に異形成があるが，MDSに関連する体細胞変異はなく，血球減少もない．

●CHIP/ICUS/CCUS/IDUSは，末梢血および/または骨髄の芽球比率が5％未満で，MDSの診断基準を満たさないMDS類似病態である．

参考文献

1）Bennett JM, Catovsky D, Daniel MT, et al：Proposals for the classification of the myelodysplastic syndromes. Br J Haematol　51：189-199，1982

2）Jacobs KB, Yeager M, Zhou W, et al：Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet　44：651-658，2012

3）Laurie CC, Laurie CA, Rice K, et al：Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet　44：642-650，2012

4）Steensma DP, Bejar R, Jaiswal S, et al：Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood　126：9-16，2015

5）Valent P, Horny HP：Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest　39：548-553，2009

6）Valent P, Bain BJ, Bennett JM, et al：Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leuk Res　36：1-5，2012

7）Kwok B, Hall JM, Witte JS, et al：MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood　126：2355-2361，2015

8）Valent P, Jäger E, Mitterbauer-Hohendanner G, et al：Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis. Am J Cancer Res　1：531-541，2011

9）Valent P, Orazi A, Steensma DP, et al：Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget　8：73483-73500，2017

10）Welch JS, Ley TJ, Link DC, et al：The origin and evolution of mutations in acute myeloid leukemia. Cell　150：264-278，2012

11）Papaemmanuil E, Gerstung M, Malcovati L, et al：Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood　122：3616-3627，2013

12）Cargo CA, Rowbotham N, Evans PA, et al：Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood　126：2362-2365，2015

13）Malcovati L, Gallì A, Travaglino E, et al：Clinical significance of somatic mutation in unexplained blood cytopenia. Blood　129：3371-3378，2017

14）Jaiswal S, Fontanillas P, Flannick J, et al：Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med　371：2488-2498，2014

15）Genovese G, Kähler AK, Handsaker RE, et al：Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med　371：2477-2487，2014

16）Steensma DP：New challenges in evaluating anemia in older persons in the era of molecular testing. Hematology Am Soc Hematol Educ Program　2016：67-73，2016

17）Jaiswal S, Natarajan P, Silver AJ, et al：Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med　377：111-121，2017

18）Fuster JJ, MacLauchlan S, Zuriaga MA, et al：Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science　355：842-847，2017

19）Karner K, George TI, Patel JL：Current Aspects of Clonal Hematopoiesis: Implications for Clinical Diagnosis. Ann Lab Med　39：509-514，2019

20）Yoshizato T, Dumitriu B, Hosokawa K, et al：Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med　373：35-47，2015

21）Swerdlow SH, Campo E, Harris NL, et al：WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, Revised ed, IARC Press，Lyon，2017